Can MPN patients develop biological markers that influence their current therapies? Yes, says MPN expert Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center. Dr. Verstovsek discusses genetic mutations and drug resistance and what researchers are doing to stay ahead. He remains optimistic for the future as clinical trials continue to indicate increased benefits to the MPN patient population.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo